Impact of obesity on cardiac metabolism, fibrosis, and function

Trends in Cardiovascular Medicine

Volumn 25, Issue 2, 2015, Pages 119-126

  Mahajan, Rajiv ^a   Lau, Dennis H ^a   Sanders, Prashanthan ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; CYTOKINE; ENDOTHELIN 1; MATRIX METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA1;

ADIPOSE TISSUE; ANATOMY; CARDIOMYOPATHY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; EPICARDIUM; HEART ATRIUM ENLARGEMENT; HEART ATRIUM FIBRILLATION; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART MUSCLE METABOLISM; HEART MUSCLE OXYGEN CONSUMPTION; HUMAN; INFLAMMATION; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; NONHUMAN; OBESITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; WEIGHT REDUCTION; ATRIAL FIBRILLATION; COMPLICATION; CORONARY ARTERY DISEASE; ENDOMYOCARDIAL FIBROSIS; HEART; PATHOPHYSIOLOGY; PHYSIOLOGY;

ATRIAL FIBRILLATION; CORONARY ARTERY DISEASE; ENDOMYOCARDIAL FIBROSIS; HEART; HUMANS; OBESITY;

EID: 84923101242     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2014.09.005     Document Type: Review

References (90)

1. Ogden C.L., Carroll M.D., Kit B.K., Flegal K.M. Prevalence of childhood and adult obesity in the United States, 2011-2012. J Am Med Assoc 2014, 311:806-814.
2. Ng M., Fleming T., Robinson M., Thomson B., Graetz N., Margono C., et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014, 384:766-781.
3. Walls H.L., Magliano D.J., Stevenson C.E., Backholer K., Mannan H.R., Shaw J.E., et al. Projected progression of the prevalence of obesity in Australia. Obesity (Silver Spring) 2012, 20:872-878.
4. Kenchaiah S., Evans J.C., Levy D., Wilson P.W., Benjamin E.J., Larson M.G., et al. Obesity and the risk of heart failure. N Engl J Med 2002, 347:305-313.
5. Barbosa M.M., Beleigoli A.M., de Fatima Diniz M., Freire C.V., Ribeiro A.L., Nunes M.C. Strain imaging in morbid obesity: insights into subclinical ventricular dysfunction. Clin Cardiol 2011, 34:288-293.
6. Tumuklu M.M., Etikan I., Kisacik B., Kayikcioglu M. Effect of obesity on left ventricular structure and myocardial systolic function: assessment by tissue Doppler imaging and strain/strain rate imaging. Echocardiography 2007, 24:802-809.
7. Peterson L.R., Waggoner A.D., Schechtman K.B., Meyer T., Gropler R.J., Barzilai B., et al. Alterations in left ventricular structure and function in young healthy obese women: assessment by echocardiography and tissue Doppler imaging. J Am Coll Cardiol 2004, 43:1399-1404.
8. Wong C.Y., O'Moore-Sullivan T., Leano R., Byrne N., Beller E., Marwick T.H. Alterations of left ventricular myocardial characteristics associated with obesity. Circulation 2004, 110:3081-3087.
9. 2). Am J Cardiol 2004, 94:1087-1090.
10. Di Bello V., Santini F., Di Cori A., Pucci A., Palagi C., Delle Donne M.G., et al. Obesity cardiomyopathy: is it a reality? An ultrasonic tissue characterization study. J Am Soc Echocardiogr 2006, 19:1063-1071.
11. Glenn D.J., Wang F., Nishimoto M., Cruz M.C., Uchida Y., Holleran W.M., et al. A murine model of isolated cardiac steatosis leads to cardiomyopathy. Hypertension 2011, 57:216-222.
12. Sun X., Pan H., Tan H., Yu Y. High free fatty acids level related with cardiac dysfunction in obese rats. Diabetes Res Clin Pract 2012, 95:251-259.
13. Zhou Y.T., Grayburn P., Karim A., Shimabukuro M., Higa M., Baetens D., et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A 2000, 97:1784-1789.
14. Verreth W., De Keyzer D., Pelat M., Verhamme P., Ganame J., Bielicki J.K., et al. Weight loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice. Circulation 2004, 110:3259-3269.
15. Buchanan J., Mazumder P.K., Hu P., Chakrabarti G., Roberts M.W., Yun U.J., et al. Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 2005, 146:5341-5349.
16. Park S.Y., Cho Y.R., Kim H.J., Higashimori T., Danton C., Lee M.K., et al. Unraveling the temporal pattern of diet-induced insulin resistance in individual organs and cardiac dysfunction in C57BL/6 mice. Diabetes 2005, 54:3530-3540.
17. Christoffersen C., Bollano E., Lindegaard M.L., Bartels E.D., Goetze J.P., Andersen C.B., et al. Cardiac lipid accumulation associated with diastolic dysfunction in obese mice. Endocrinology 2003, 144:3483-3490.
18. Carroll J.F., Zenebe W.J., Strange T.B. Cardiovascular function in a rat model of diet-induced obesity. Hypertension 2006, 48:65-72.
19. Abed H.S., Samuel C.S., Lau D.H., Kelly D.J., Royce S.G., Alasady M., et al. Obesity results in progressive atrial structural and electrical remodeling: implications for atrial fibrillation. Heart Rhythm 2013, 10:90-100.
20. Leichman J.G., Aguilar D., King T.M., Vlada A., Reyes M., Taegtmeyer H. Association of plasma free fatty acids and left ventricular diastolic function in patients with clinically severe obesity. Am J Clin Nutr 2006, 84:336-341.
21. Alaud-din A., Meterissian S., Lisbona R., MacLean L.D., Forse R.A. Assessment of cardiac function in patients who were morbidly obese. Surgery 1990, 108:809-818.
22. de Divitiis O., Fazio S., Petitto M., Maddalena G., Contaldo F., Mancini M. Obesity and cardiac function. Circulation 1981, 64:477-482.
23. Pascual M., Pascual D.A., Soria F., Vicente T., Hernandez A.M., Tebar F.J., et al. Effects of isolated obesity on systolic and diastolic left ventricular function. Heart 2003, 89:1152-1156.
24. Manrique C., DeMarco V.G., Aroor A.R., Mugerfeld I., Garro M., Habibi J., et al. Obesity and insulin resistance induce early development of diastolic dysfunction in young female mice fed a Western diet. Endocrinology 2013, 154:3632-3642.
25. Carroll J.F., Summers R.L., Dzielak D.J., Cockrell K., Montani J.P., Mizelle H.L. Diastolic compliance is reduced in obese rabbits. Hypertension 1999, 33:811-815.
26. Cuspidi C., Rescaldani M., Sala C., Grassi G. Left-ventricular hypertrophy and obesity: a systematic review and meta-analysis of echocardiographic studies. J Hypertens 2014, 32:16-25.
27. Rider O.J., Lewandowski A., Nethononda R., Petersen S.E., Francis J.M., Pitcher A., et al. Gender-specific differences in left ventricular remodelling in obesity: insights from cardiovascular magnetic resonance imaging. Eur Heart J 2013, 34:292-299.
28. Di Salvo G., Pacileo G., Del Giudice E.M., Natale F., Limongelli G., Verrengia M., et al. Atrial myocardial deformation properties in obese nonhypertensive children. J Am Soc Echocardiogr 2008, 21:151-156.
29. Wang T.J., Parise H., Levy D., D'Agostino R.B., Wolf P.A., Vasan R.S., et al. Obesity and the risk of new-onset atrial fibrillation. J Am Med Assoc 2004, 292:2471-2477.
30. Ito K., Date T., Kawai M., Nojiri A., Narui R., Hioki M., et al. Morphological change of left atrium in obese individuals. Int J Cardiol 2011, 152:117-119.
31. Wong C.X., Abed H.S., Molaee P., Nelson A.J., Brooks A.G., Sharma G., et al. Pericardial fat is associated with atrial fibrillation severity and ablation outcome. J Am Coll Cardiol 2011, 57:1745-1751.
32. Thanassoulis G., Massaro J.M., O'Donnell C.J., Hoffmann U., Levy D., Ellinor P.T., et al. Pericardial fat is associated with prevalent atrial fibrillation: the Framingham Heart Study. Circ Arrhythm Electrophysiol 2010, 3:345-350.
33. Peterson L.R., Herrero P., Schechtman K.B., Racette S.B., Waggoner A.D., Kisrieva-Ware Z., et al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 2004, 109:2191-2196.
34. Szczepaniak L.S., Dobbins R.L., Metzger G.J., Sartoni-D'Ambrosia G., Arbique D., Vongpatanasin W., et al. Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med 2003, 49:417-423.
35. Boudina S., Sena S., O'Neill B.T., Tathireddy P., Young M.E., Abel E.D. Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity. Circulation 2005, 112:2686-2695.
36. Laimer M., Kaser S., Kranebitter M., Sandhofer A., Muhlmann G., Schwelberger H., et al. Effect of pronounced weight loss on the nontraditional cardiovascular risk marker matrix metalloproteinase-9 in middle-aged morbidly obese women. Int J Obes (Lond) 2005, 29:498-501.
37. Eschalier R., Rossignol P., Kearney-Schwartz A., Adamopoulos C., Karatzidou K., Fay R., et al. Features of cardiac remodeling, associated with blood pressure and fibrosis biomarkers, are frequent in subjects with abdominal obesity. Hypertension 2014, 63:740-746.
38. Oliveira-Junior S.A., Martinez P.F., Guizoni D.M., Campos D.H., Fernandes T., Oliveira E.M., et al. AT1 receptor blockade attenuates insulin resistance and myocardial remodeling in rats with diet-induced obesity. PLoS One 2014, 9:e86447.
39. Takatsu M., Nakashima C., Takahashi K., Murase T., Hattori T., Ito H., et al. Calorie restriction attenuates cardiac remodeling and diastolic dysfunction in a rat model of metabolic syndrome. Hypertension 2013, 62:957-965.
40. Venteclef N., Guglielmi V., Balse E., Gaborit B., Cotillard A., Atassi F., et al. Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipo-fibrokines. Eur Heart J 2013, 10.1093/eurheartj/eht099.
41. Mahajan R., Kuklik P., Grover S., Brooks A.G., Wong C.X., Sanders P., et al. Cardiovascular magnetic resonance of total and atrial pericardial adipose tissue: a validation study and development of a 3 dimensional pericardial adipose tissue model. J Cardiovasc Magn Reson 2013, 15:73.
42. Lim J., Iyer A., Liu L., Suen J.Y., Lohman R.J., Seow V., et al. Diet-induced obesity, adipose inflammation, and metabolic dysfunction correlating with PAR2 expression are attenuated by PAR2 antagonism. FASEB J 2013, 27:4757-4767.
43. Ghanim H., Aljada A., Hofmeyer D., Syed T., Mohanty P., Dandona P. Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation 2004, 110:1564-1571.
44. Kosmala W., Przewlocka-Kosmala M., Szczepanik-Osadnik H., Mysiak A., Marwick T.H. Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade. Heart 2013, 99:320-326.
45. Toblli J.E., Cao G., DeRosa G., Forcada P. Reduced cardiac expression of plasminogen activator inhibitor 1 and transforming growth factor beta1 in obese Zucker rats by perindopril. Heart 2005, 91:80-86.
46. Zamani N., Brown C.W. Emerging roles for the transforming growth factor-{beta} superfamily in regulating adiposity and energy expenditure. Endocr Rev 2011, 32:387-403.
47. Alessi M.C., Bastelica D., Morange P., Berthet B., Leduc I., Verdier M., et al. Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes 2000, 49:1374-1380.
48. Carroll J.F., Tyagi S.C. Extracellular matrix remodeling in the heart of the homocysteinemic obese rabbit. Am J Hypertens 2005, 18(5 Pt 1):692-698.
49. Verheule S., Sato T., Everett T., Engle S.K., Otten D., Rubart-von der Lohe M., et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Circ Res 2004, 94:1458-1465.
50. Lijnen P.J., Petrov V.V., Fagard R.H. Induction of cardiac fibrosis by transforming growth factor-beta(1). Mol Genet Metab 2000, 71:418-435.
51. Rahmutula D., Marcus G.M., Wilson E.E., Ding C.H., Xiao Y., Paquet A.C., et al. Molecular basis of selective atrial fibrosis due to overexpression of transforming growth factor-beta1. Cardiovasc Res 2013, 99:769-779.
52. Gramley F., Lorenzen J., Koellensperger E., Kettering K., Weiss C., Munzel T. Atrial fibrosis and atrial fibrillation: the role of the TGF-beta1 signaling pathway. Int J Cardiol 2010, 143:405-413.
53. Verrecchia F., Chu M.L., Mauviel A. Identification of novel TGF-beta/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J Biol Chem 2001, 276:17058-17062.
54. Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 2004, 63:423-432.
55. Santander C., Brandan E. Betaglycan induces TGF-beta signaling in a ligand-independent manner, through activation of the p38 pathway. Cell Signal 2006, 18:1482-1491.
56. Liu S., Xu S.W., Kennedy L., Pala D., Chen Y., Eastwood M., et al. FAK is required for TGFbeta-induced JNK phosphorylation in fibroblasts: implications for acquisition of a matrix-remodeling phenotype. Mol Biol Cell 2007, 18:2169-2178.
57. Leask A., Abraham D.J. All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci 2006, 119(Pt 23):4803-4810.
58. Leask A. Targeting the TGFbeta, endothelin-1 and CCN2 axis to combat fibrosis in scleroderma. Cell Signal 2008, 20:1409-1414.
59. Weil B.R., Westby C.M., Van Guilder G.P., Greiner J.J., Stauffer B.L., DeSouza C.A. Enhanced endothelin-1 system activity with overweight and obesity. Am J Physiol Heart Circ Physiol 2011, 301:H689-H695.
60. Adiarto S., Emoto N., Iwasa N., Yokoyama M. Obesity-induced upregulation of myocardial endothelin-1 expression is mediated by leptin. Biochem Biophys Res Commun 2007, 353:623-627.
61. Mayyas F., Niebauer M., Zurick A., Barnard J., Gillinov A.M., Chung M.K., et al. Association of left atrial endothelin-1 with atrial rhythm, size, and fibrosis in patients with structural heart disease. Circ Arrhythm Electrophysiol 2010, 3:369-379.
62. Nakazawa Y., Ashihara T., Tsutamoto T., Ito M., Horie M. Endothelin-1 as a predictor of atrial fibrillation recurrence after pulmonary vein isolation. Heart Rhythm 2009, 6:725-730.
63. Shi-wen X., Kennedy L., Renzoni E.A., Bou-Gharios G., du Bois R.M., Black C.M., et al. Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblasts. Arthritis Rheum 2007, 56:4189-4194.
64. Belloni A.S., Rossi G.P., Andreis P.G., Neri G., Albertin G., Pessina A.C., et al. Endothelin adrenocortical secretagogue effect is mediated by the B receptor in rats. Hypertension 1996, 27:1153-1159.
65. Recchia A.G., Filice E., Pellegrino D., Dobrina A., Cerra M.C., Maggiolini M. Endothelin-1 induces connective tissue growth factor expression in cardiomyocytes. J Mol Cell Cardiol 2009, 46:352-359.
66. Seccia T.M., Belloni A.S., Kreutz R., Paul M., Nussdorfer G.G., Pessina A.C., et al. Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II. J Am Coll Cardiol 2003, 41:666-673.
67. Adiarto S., Heiden S., Vignon-Zellweger N., Nakayama K., Yagi K., Yanagisawa M., et al. ET-1 from endothelial cells is required for complete angiotensin II-induced cardiac fibrosis and hypertrophy. Life Sci 2012, 91:651-657.
68. Goossens G.H., Bizzarri A., Venteclef N., Essers Y., Cleutjens J.P., Konings E., et al. Increased adipose tissue oxygen tension in obese compared with lean men is accompanied by insulin resistance, impaired adipose tissue capillarization, and inflammation. Circulation 2011, 124:67-76.
69. Pasarica M., Sereda O.R., Redman L.M., Albarado D.C., Hymel D.T., Roan L.E., et al. Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response. Diabetes 2009, 58:718-725.
70. Ye J., Gao Z., Yin J., He Q. Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Endocrinol Metab 2007, 293:E1118-E1128.
71. Rausch M.E., Weisberg S., Vardhana P., Tortoriello D.V. Obesity in C57BL/6J mice is characterized by adipose tissue hypoxia and cytotoxic T-cell infiltration. Int J Obes (Lond) 2008, 32:451-463.
72. Sun K., Halberg N., Khan M., Magalang U.J., Scherer P.E. Selective inhibition of hypoxia-inducible factor 1alpha ameliorates adipose tissue dysfunction. Mol Cell Biol 2013, 33:904-917.
73. Yang R., Barouch L.A. Leptin signaling and obesity: cardiovascular consequences. Circ Res 2007, 101:545-559.
74. Ochiai H., Shirasawa T., Nishimura R., Nanri H., Ohtsu T., Hoshino H., et al. Abdominal obesity and serum adiponectin complexes among population-based elementary school children in Japan: a cross-sectional study. BMC Pediatr 2014, 14:81.
75. Martinez-Martinez E., Jurado-Lopez R., Valero-Munoz M., Bartolome M.V., Ballesteros S., Luaces M., et al. Leptin induces cardiac fibrosis through galectin-3, mTOR and oxidative stress: potential role in obesity. J Hypertens 2014, 32:1104-1114. [discussion 14].
76. Zibadi S., Cordova F., Slack E.H., Watson R.R., Larson D.F. Leptin's regulation of obesity-induced cardiac extracellular matrix remodeling. Cardiovasc Toxicol 2011, 11:325-333.
77. Fukui A., Takahashi N., Nakada C., Masaki T., Kume O., Shinohara T., et al. Role of leptin signaling in the pathogenesis of angiotensin II-mediated atrial fibrosis and fibrillation. Circ Arrhythm Electrophysiol 2013, 6:402-409.
78. Madani S., De Girolamo S., Munoz D.M., Li R.K., Sweeney G. Direct effects of leptin on size and extracellular matrix components of human pediatric ventricular myocytes. Cardiovasc Res 2006, 69:716-725.
79. Schram K., Wong M.M., Palanivel R., No E.K., Dixon I.M., Sweeney G. Increased expression and cell surface localization of MT1-MMP plays a role in stimulation of MMP-2 activity by leptin in neonatal rat cardiac myofibroblasts. J Mol Cell Cardiol 2008, 44:874-881.
80. Leifheit-Nestler M., Wagner N.M., Gogiraju R., Didie M., Konstantinides S., Hasenfuss G., et al. Importance of leptin signaling and signal transducer and activator of transcription-3 activation in mediating the cardiac hypertrophy associated with obesity. J Transl Med 2013, 11:170.
81. Fujita K., Maeda N., Sonoda M., Ohashi K., Hibuse T., Nishizawa H., et al. Adiponectin protects against angiotensin II-induced cardiac fibrosis through activation of PPAR-alpha. Arterioscler Thromb Vasc Biol 2008, 28:863-870.
82. Ybarra J., Resmini E., Planas F., Navarro-Lopez F., Webb S., Pou J.M., et al. Relationship between adiponectin and left atrium size in uncomplicated obese patients: adiponectin, a link between fat and heart. Obes Surg 2009, 19:1324-1332.
83. Hatem S.N., Sanders P. Epicardial adipose tissue and atrial fibrillation. Cardiovasc Res 2014, 102:205-213.
84. Cherian S., Lopaschuk G.D., Carvalho E. Cellular cross-talk between epicardial adipose tissue and myocardium in relation to the pathogenesis of cardiovascular disease. Am J Physiol Endocrinol Metab 2012, 303:E937-E949.
85. Wang H.T., Liu C.F., Tsai T.H., Chen Y.L., Chang H.W., Tsai C.Y., et al. Effect of obesity reduction on preservation of heart function and attenuation of left ventricular remodeling, oxidative stress and inflammation in obese mice. J Transl Med 2012, 10:145.
86. Grapsa J., Tan T.C., Paschou S.A., Kalogeropoulos A.S., Shimony A., Kaier T., et al. The effect of bariatric surgery on echocardiographic indices: a review of the literature. Eur J Clin Invest 2013, 43:1224-1230.
87. De Ciuceis C., Rossini C., Porteri E., La Boria E., Corbellini C., Mittempergher F., et al. Circulating endothelial progenitor cells, microvascular density and fibrosis in obesity before and after bariatric surgery. Blood Press 2013, 22:165-172.
88. Garcia de la Torre N., Rubio M.A., Bordiu E., Cabrerizo L., Aparicio E., Hernandez C., et al. Effects of weight loss after bariatric surgery for morbid obesity on vascular endothelial growth factor-A, adipocytokines, and insulin. J Clin Endocrinol Metab 2008, 93:4276-4281.
89. Abed H.S., Wittert G.A., Leong D.P., Shirazi M.G., Bahrami B., Middeldorp M.E., et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. J Am Med Assoc 2013, 310:2050-2060.
90. Pathak R.K., Middeldorp M.E., Lau D.H., Mehta A.B., Mahajan R., Twomey D., et al. Aggressive Risk factor REduction STudy for Atrial Fibrillation (ARREST-AF cohort study): implications for the outcome of ablation. J Am Coll Cardiol 2014, [In Press].